Remi A. Nout
Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects.
Overview
Remi Nout is a radiation oncologist who trained in the Leiden PORTEC group and now leads radiation oncology at Erasmus MC in Rotterdam. He was first author of the 2010 Lancet report of PORTEC-2, in which vaginal brachytherapy gave vaginal recurrence control equivalent to external-beam pelvic radiotherapy in high-intermediate-risk endometrial cancer with less bowel toxicity and better quality of life, making brachytherapy the standard adjuvant treatment for this group. He also leads international trials in cervical cancer radiotherapy.
Similar pages
not linked directly; found by shared links- PersonAmanda Nickles Fader
Shares Endometrial cancer and the tags endometrial, trialist.
- PersonCarien L. Creutzberg
Shares Endometrial cancer and the tags endometrial, radiotherapy.
- PersonShannon N. Westin
Shares Endometrial cancer and the tags endometrial, trialist.
- PersonAna Oaknin
Shares Endometrial cancer, Cervical cancer and the tags endometrial, trialist.
- PersonMansoor Raza Mirza
Shares Endometrial cancer and the tags endometrial, trialist.
- PersonVicky Makker
Shares Endometrial cancer and the tags endometrial, trialist.
- PersonChris C. Parker
Shares the tags radiotherapy, trialist.
- PersonDavid Dearnaley
Shares the tags radiotherapy, trialist.